Accessibility Menu
Psychemedics logo

Psychemedics(OTC) PMD

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-32%
5 Year-62%
1 Year+13%
1 Month+13%
N/A
Psychemedics last closing stock price
MetricPriceDate
Last closeUSD 2.492026-07-23
Psychemedics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 2.492026-07-10
1 month+13.18%USD 2.202026-06-23
3 month+13.18%USD 2.202026-04-22
Year to date+55.63%USD 1.602025-12-31
1 year+12.67%USD 2.212025-07-23
3 year-50.2%USD 5.002023-07-24
5 year-61.81%USD 6.522021-07-23
Since inception-31.87%USD 3.651992-06-15

Psychemedics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$19.69M

Net Income (TTM)

-$1.86M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 10, 2025

PMD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Psychemedics

Psychemedics Corporation, established in 1986 and based in Acton, Massachusetts, specializes in drug abuse detection services through hair sample analysis. The company operates in the United States, Brazil, and internationally, providing comprehensive testing for a wide range of substances.

Products and Services
  • Hair sample analysis for drug detection
  • Testing for a broad spectrum of substances, including opioids and synthetic cannabinoids
  • Services for employers, treatment professionals, and law enforcement agencies
Growth Outlook
  • Recent quarterly revenue of $4.43 million shows potential for recovery
  • Gross profit margin improved to 31.37% in Q4 2024
  • Expansion into international markets may drive future growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of $20.5 million indicates stable performance
  • Net income of $189,000 in Q4 2024 marks a positive shift
  • Current ratio of 1.82 suggests strong liquidity position
Psychemedics Corporation is positioned in the medical diagnostics and research industry, focusing on drug testing solutions that adhere to industry standards. The company's innovative approach to drug detection through hair analysis provides clients with detailed insights into substance use patterns over time. This capability is particularly valuable for employers and treatment professionals seeking to address substance abuse issues effectively. The growth outlook for Psychemedics appears promising, with recent financial data indicating a potential turnaround. The improvement in gross profit margins and the recent quarterly revenue highlight the company's ability to adapt and respond to market demands. Furthermore, the expansion into international markets could provide additional revenue streams, enhancing overall growth prospects. Financially, the company has demonstrated resilience, with a TTM revenue of $20.5 million and a positive net income in the latest quarter. The strong current ratio reflects a solid liquidity position, allowing for operational flexibility. Overall, Psychemedics Corporation presents an intriguing opportunity for investors interested in the healthcare sector, particularly in the area of drug abuse detection and prevention.
AI Generated • Aug 22, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

101

CEO

Brian Hullinger

Website

www.psychemedics.com

Headquarters

Acton, MA 01720, US

PMD Financials

Key Financial Metrics (TTM)

Gross Margin

36.07%

Operating Margin

-9.62%

Net Income Margin

-9.45%

Return on Equity

-31.54%

Return on Capital

-30.07%

Return on Assets

-22.37%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$7.10M

Operating Income

-$1.89M

EBITDA

$191.00K

Operating Cash Flow

$929.00K

Capital Expenditure

-$56.00K

Free Cash Flow

$873.00K

Cash & ST Invst.

$1.42M

Total Debt

$1.17M

Psychemedics Performance Analysis

Psychemedics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 24,909,000N/A
20222022-12-31USD 25,240,0001.3%
20232023-12-31USD 22,098,000-12.4%
20242024-12-31USD 19,685,000-10.9%
Psychemedics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-317.2%
Q22024-06-30-11.7%
Q32024-09-309.5%
Q42024-12-31-14.5%
Psychemedics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.12N/A
20222022-12-31USD -0.1960.9%
20232023-12-31USD -0.72275.6%
20242024-12-31USD -0.32-56.2%
Psychemedics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-3125.0%
Q22024-06-30-16.7%
Q32024-09-3035.1%
Q42024-12-31135.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

$4.43M

-11.5%

Gross Profit

$1.39M

-32.6%

Gross Margin

31.37%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

116

N/A

Net Income

$189.00K

+120.0%

EBITDA

$584.00K

+299.3%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

$1.42M

-27.9%

Total Debt

$1.17M

-49.3%

Accounts Receivable

$2.52M

-31.9%

Inventory

$0.00

N/A

Long Term Debt

$477.00K

-49.5%

Short Term Debt

$689.00K

-71.3%

Return on Assets

-22.37%

N/A

Return on Invested Capital

-33.76%

N/A

Free Cash Flow

$993.00K

+48.9%

Operating Cash Flow

$1.02M

+53.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CEMIChembio Diagnostics, Inc.
$0.46+0.22%
TMDITitan Medical Inc.
$0.14+0.00%
WENAAnew Medical, Inc.
$0.73-3.84%
TLPHTalphera, Inc.
$1.18-0.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$14.06+0.06%
NVDANvidia
$217.44-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.33-0.06%
INTCIntel
$88.97-0.01%

Questions About PMD

What is the current price of Psychemedics?

Psychemedics is trading at N/A per share.

What is the 52-week range for Psychemedics?

Over the past 52 weeks, Psychemedics has traded between N/A and N/A.

How much debt does Psychemedics have?

As of the most recent reporting period, Psychemedics reported total debt of $1.17M.

How much cash does Psychemedics have on hand?

Psychemedics reported $1.42M in cash and cash equivalents in its most recent financial results.

What is Psychemedics’s dividend yield?

Psychemedics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services